The global heart attack diagnostics market size is expected to reach USD 18.52 billion by 2030, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to grow at a CAGR of 8.2% during the forecast year from 2024 to 2030. The overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth.

 

Access the Heart Attack Diagnostics Market Size, Share & Trends Analysis Report By Test (Electrocardiogram, Blood Test), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2024 – 2030

 

The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market. 

 

Heart Attack Diagnostics Market Report Highlights

·        North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.

 

·        The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.

 

·        The Troponin segment dominated the blood tests market and accounted for a share of 62.5% in 2023. Troponin T, a protein present in the heart muscle, is crucial in diagnosing heart attacks through a high-sensitivity troponin T test.

 

Key Heart Attack Diagnostics Company Insights

The surge in competition is driving rapid technological progress, prompting companies to enhance their products through extensive research and development efforts. Leading companies are adopting various strategic approaches like mergers & acquisitions, partnerships, and new product introductions to increase their market presence.

 

Order your free sample copy of “Heart Attack Diagnostics Market Report 2024 - 2030, published by Grand View Research

 

Key Heart Attack Diagnostics Companies:

The following are the leading companies in the heart attack diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

 

·        GE Healthcare

·        Hitachi Corporation

·        Koninklijke Philips NV

·        Midmark Corporation

·        F Hoffmann-La Roche Ltd

·        Schiller AG

·        Siemens Healthineers

·        Toshiba Corporation

·        Welch Allyn Inc

·        Astrazenca PLC

 

Recent Developments

·        In June 2024, Philips announced the launch of Philips Cardiac Workstation aims to transform diagnostic cardiology with introduction of new Cardiac Workstation, to enhance cardiology patients care and accelerate clinical decision making in Middle East and Africa (MEA) and Europe

·        In April 2024, GE Healthcare introduced Caption AI on Vscan Air SL to expand cardiac care access by allowing more clinicians/medical professional capture diagnostic-quality cardiac images.

 

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  
sales@grandviewresearch.com